ADMA Biologics, Inc.(ADMA)Earnings, Financials & Key Ratios

ADMA•NASDAQ

$10.08

$2.46B mkt cap·16.8× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Show more

Revenue$510M+19.6%
EBITDA$200M+35.7%
Net Income$147M-25.7%
EPS (Diluted)0.60-25.9%
Gross Margin57.39%+11.5%
EBITDA Margin39.11%+13.4%
Operating Margin37.53%+15.1%
Net Margin28.8%-37.9%
ROE35.56%-56.4%
ROIC36.01%-4.4%
Debt/Equity0.17-28.9%
Interest Coverage26.69+166.2%

Technical→

ADMA Key Insights

ADMA Biologics, Inc. (ADMA) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 32.5%
✓Strong 5Y sales CAGR of 64.6%

✗Weaknesses

✗Weak momentum: RS Rating 9 (bottom 9%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ADMA Price & Volume

ADMA Biologics, Inc. (ADMA) stock price & volume — 10-year historical chart

Loading chart...

ADMA Growth Metrics

ADMA Biologics, Inc. (ADMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years53.17%

5 Years64.6%

3 Years49.05%

TTM19.63%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-25.67%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-26.41%

Return on Capital

10 Years-28.93%

5 Years8.8%

3 Years28.37%

Last Year38.76%

ADMA Recent Earnings

ADMA Biologics, Inc. (ADMA) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)

Q1 2026Latest

Feb 25, 2026

EPS

$0.20

Est $0.18

+8.1%

Revenue

$139M

Est $140M

-0.3%

Q4 2025

Nov 5, 2025

EPS

$0.16

Est $0.16

+0.0%

Revenue

$134M

Est $140M

-4.0%

Q3 2025

Aug 6, 2025

EPS

$0.15

Est $0.14

+7.1%

Revenue

$122M

Est $130M

-6.4%

Q2 2025

May 7, 2025

EPS

$0.14

Est $0.16

-12.5%

Revenue

$115M

Est $122M

-5.7%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 25, 2026	$0.20vs $0.18+8.1%	$139Mvs $140M-0.3%
Q4 2025	Nov 5, 2025	$0.16vs $0.16+0.0%	$134Mvs $140M-4.0%
Q3 2025	Aug 6, 2025	$0.15vs $0.14+7.1%	$122Mvs $130M-6.4%
Q2 2025	May 7, 2025	$0.14vs $0.16-12.5%	$115Mvs $122M-5.7%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
GRFSGrifols, S.A.Direct Competitor	7.11B	8.41	12.57	0.2%	5.34%	5.16%	1.15
BIOBio-Rad Laboratories, Inc.Direct Competitor	6.99B	259.02	9.29	0.65%	6.52%	2.4%	0.21
PRPHProPhase Labs, Inc.Direct Competitor	5.82M	0.14	-0.05	-84.75%	-38.72%	-6.08%	3.34
HALOHalozyme Therapeutics, Inc.Direct Competitor	7.81B	66.35	25.92	37.55%	22.69%	6.49%
CSLCarlisle Companies IncorporatedProduct Competitor	15.29B	373.96	21.84	0.33%	14.57%	34.48%	1.60
TAKTakeda Pharmaceutical Company LimitedProduct Competitor	52.82B	16.72	77.66	7.45%	2.56%	1.5%	0.65
OCSLOaktree Specialty Lending CorporationProduct Competitor	1.1B	12.51	32.08	60.93%		3.45%	1.01
BHVNBiohaven Ltd.Product Competitor	1.06B	10.04	-1.46			-8.66%	5.36

Compare ADMA vs Peers

ADMA Biologics, Inc. (ADMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs GRFS

Most directly comparable listed peer for ADMA.

Scale Benchmark

vs TAK

Larger-name benchmark to compare ADMA against a more recognizable public peer.

Peer Set

Compare Top 5

vs GRFS, BIO, PRPH, HALO

ADMA Income Statement

ADMA Biologics, Inc. (ADMA) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	22.76M	16.99M	29.35M	42.22M	80.94M	154.08M	258.21M	426.45M	510.17M
Revenue Growth %	113.49%	-25.37%	72.79%	43.85%	91.72%	90.36%	67.58%	65.15%	19.63%
Cost of Goods Sold	29.16M	42.19M	39.5M	61.29M	79.77M	118.81M	169.27M	206.9M	217.41M
COGS % of Revenue	128.14%	248.42%	134.6%	145.17%	98.55%	77.11%	65.56%	48.52%	42.61%
Gross Profit	-6.4M▲ 0%	-25.21M▼ 293.7%	-10.16M▲ 59.7%	-19.07M▼ 87.8%	1.17M▲ 106.2%	35.27M▲ 2906.4%	88.94M▲ 152.2%	219.55M▲ 146.8%	292.76M▲ 33.3%
Gross Margin %	-28.14%	-148.42%	-34.6%	-45.17%	1.45%	22.89%	34.44%	51.48%	57.39%
Gross Profit Growth %	-248.92%	-293.66%	59.72%	-87.8%	106.15%	2906.39%	152.21%	146.85%	33.35%
Operating Expenses	32.06M	35.08M	31.27M	45.84M	59.55M	74.63M	67.31M	80.57M	101.32M
OpEx % of Revenue	140.86%	206.53%	106.54%	108.58%	73.57%	48.44%	26.07%	18.89%	19.86%
Selling, General & Admin	18.09M	22.5M	25.91M	35.05M	42.9M	52.46M	59.02M	74.12M	91.58M
SG&A % of Revenue	79.49%	132.48%	88.28%	83.02%	53%	34.05%	22.86%	17.38%	17.95%
Research & Development	6.23M	3.93M	2.34M	5.91M	3.65M	3.61M	3.3M	1.81M	4.76M
R&D % of Revenue	27.37%	23.11%	7.99%	13.99%	4.5%	2.35%	1.28%	0.43%	0.93%
Other Operating Expenses	-10.14K	-127.12K	3.01M	4.89M	13M	18.56M	4.99M	4.63M	4.98M
Operating Income	-39.31M▲ 0%	-60.29M▼ 53.4%	-41.42M▲ 31.3%	-64.91M▼ 56.7%	-58.37M▲ 10.1%	-39.37M▲ 32.6%	21.63M▲ 155.0%	138.98M▲ 542.5%	191.44M▲ 37.7%
Operating Margin %	-172.71%	-354.95%	-141.14%	-153.75%	-72.12%	-25.55%	8.38%	32.59%	37.53%
Operating Income Growth %	-126.83%	-53.37%	31.29%	-56.71%	10.08%	32.56%	154.95%	542.49%	37.75%
EBITDA	-38.08M	-56.84M	-38.17M	-60.97M	-52.88M	-32.25M	29.96M	147.03M	199.54M
EBITDA Margin %	-167.29%	-334.66%	-130.04%	-144.42%	-65.33%	-20.93%	11.6%	34.48%	39.11%
EBITDA Growth %	-125.82%	-49.29%	32.86%	-59.76%	13.28%	39.01%	192.91%	390.68%	35.72%
D&A (Non-Cash Add-back)	1.23M	3.45M	3.26M	3.94M	5.5M	7.11M	8.33M	8.04M	8.1M
EBIT	-40.47M	-60.22M	-39.29M	-63.76M	-58.59M	-46.63M	-3.21M	139.64M	189.77M
Net Interest Income	-3.23M	-5.33M	-8.19M	-11.7M	-13.02M	-19.23M	-23.41M	-11.83M	-5.24M
Interest Income	57.23K	195.4K	800.78K	288.13K	34.53K	44.83K	1.62M	2.1M	1.87M
Interest Expense	3.29M	5.52M	8.99M	11.99M	13.06M	19.28M	25.03M	13.93M	7.11M
Other Income/Expense	-4.45M	-5.45M	-6.85M	-10.83M	-13.27M	-26.54M	-49.87M	-13.27M	-8.79M
Pretax Income	-43.76M▲ 0%	-65.74M▼ 50.2%	-48.28M▲ 26.6%	-75.75M▼ 56.9%	-71.65M▲ 5.4%	-65.9M▲ 8.0%	-28.24M▲ 57.2%	125.71M▲ 545.2%	182.66M▲ 45.3%
Pretax Margin %	-192.26%	-387.06%	-164.5%	-179.41%	-88.52%	-42.77%	-10.94%	29.48%	35.8%
Income Tax	0	0	0	0	0	0	0	-71.96M	35.73M
Effective Tax Rate %	0%	0%	0%	0%	0%	0%	0%	-57.24%	19.56%
Net Income	-43.76M▲ 0%	-65.74M▼ 50.2%	-48.28M▲ 26.6%	-75.75M▼ 56.9%	-71.65M▲ 5.4%	-65.9M▲ 8.0%	-28.24M▲ 57.2%	197.67M▲ 800.0%	146.93M▼ 25.7%
Net Margin %	-192.26%	-387.06%	-164.5%	-179.41%	-88.52%	-42.77%	-10.94%	46.35%	28.8%
Net Income Growth %	-124.23%	-50.24%	26.56%	-56.9%	5.41%	8.02%	57.15%	800%	-25.67%
Net Income (Continuing)	-43.76M	-65.74M	-48.28M	-75.75M	-71.65M	-65.9M	-28.24M	197.67M	146.93M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-1.91▲ 0%	-1.45▲ 24.1%	-1.05▲ 27.6%	-1.02▲ 2.9%	-0.61▲ 40.2%	-0.43▲ 29.5%	-0.13▲ 69.8%	0.81▲ 723.1%	0.60▼ 25.9%
EPS Growth %	-18.63%	24.08%	27.59%	2.86%	40.2%	29.51%	69.77%	723.08%	-25.93%
EPS (Basic)	-1.91	-1.45	-1.05	-1.02	-0.61	-0.43	-0.13	0.85	0.62
Diluted Shares Outstanding	22.9M	45.19M	54.35M	86.15M	139.58M	197.87M	223.98M	243.34M	244.9M
Basic Shares Outstanding	22.9M	45.19M	54.35M	86.15M	139.58M	197.87M	223.98M	233.08M	238.3M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

ADMA Balance Sheet

ADMA Biologics, Inc. (ADMA) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	63.17M	44.53M	85.82M	153.74M	208.73M	270.4M	257.01M	331.41M	466.51M
Cash & Short-Term Investments	43.11M	22.75M	26.75M	55.92M	51.09M	86.52M	51.35M	103.15M	87.63M
Cash Only	43.11M	22.75M	26.75M	55.92M	51.09M	86.52M	51.35M	103.15M	87.63M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	3.88M	1.39M	3.47M	13.24M	28.58M	15.51M	27.42M	50M	158.43M
Days Sales Outstanding	62.22	29.92	43.15	114.44	128.86	36.73	38.76	42.79	113.35
Inventory	12.63M	18.62M	53.06M	81.54M	124.72M	163.28M	172.91M	170.24M	206.47M
Days Inventory Outstanding	158.05	161.04	490.29	485.56	570.69	501.6	372.83	300.32	346.63
Other Current Assets	2.05M	1.77M	0	0	0	5.09M	5.33M	8.03M	13.99M
Total Non-Current Assets	44.85M	44.35M	41.27M	53.93M	67.52M	78.06M	72.17M	157.27M	157.73M
Property, Plant & Equipment	30.47M	30.12M	32.99M	45.85M	58.2M	68.75M	63.47M	63.34M	71.71M
Fixed Asset Turnover	0.75x	0.56x	0.89x	0.92x	1.39x	2.24x	4.07x	6.73x	7.11x
Goodwill	3.53M	3.53M	3.53M	3.53M	3.53M	3.53M	3.53M	3.53M	3.53M
Intangible Assets	4.85M	4M	3.16M	2.44M	1.73M	1.01M	499K	460K	632K
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	6.01M	6.7M	1.6M	2.11M	4.07M	4.77M	4.67M	5.66M	8.6M
Total Assets	108.02M▲ 0%	88.88M▼ 17.7%	127.09M▲ 43.0%	207.67M▲ 63.4%	276.25M▲ 33.0%	348.46M▲ 26.1%	329.18M▼ 5.5%	488.68M▲ 48.5%	624.24M▲ 27.7%
Asset Turnover	0.21x	0.19x	0.23x	0.20x	0.29x	0.44x	0.78x	0.87x	0.82x
Asset Growth %	356.06%	-17.72%	43%	63.41%	33.02%	26.14%	-5.53%	48.45%	27.74%
Total Current Liabilities	9.44M	9.63M	14.03M	19.95M	30.38M	39.27M	49.81M	55.54M	69.54M
Accounts Payable	5.92M	5.9M	9.17M	11.07M	12.43M	13.23M	15.66M	20.22M	22.52M
Days Payables Outstanding	74.1	51.04	84.77	65.95	56.87	40.64	33.77	35.67	37.81
Short-Term Debt	0	29.98K	0	0	0	0	0	0	3.91M
Deferred Revenue (Current)	142.83K	142.83K	142.83K	142.83K	142.83K	143K	182K	143K	1.41M
Other Current Liabilities	0	-59.97K	0	207.26K	16.05M	1.8M	2.37M	1.85M	41.71M
Current Ratio	6.69x	4.63x	6.12x	7.71x	6.87x	6.89x	5.16x	5.97x	6.71x
Quick Ratio	5.35x	2.69x	2.34x	3.62x	2.77x	2.73x	1.69x	2.90x	3.74x
Cash Conversion Cycle	146.17	139.92	448.68	534.05	642.68	497.69	377.83	307.44	422.17
Total Non-Current Liabilities	58.25M	59.48M	86.87M	99.48M	104.7M	157.22M	144.17M	84.12M	77.38M
Long-Term Debt	42.97M	44.08M	83.2M	92.97M	94.87M	142.83M	130.59M	72.34M	75.98M
Capital Lease Obligations	0	119.08K	1.3M	4.33M	7.46M	10.7M	9.78M	8.56M	0
Deferred Tax Liabilities	0	-40.53M	0	0	0	0	0	0	0
Other Non-Current Liabilities	12.73M	12.88M	106.57K	54.89K	397.35K	1.85M	2.11M	1.67M	1.41M
Total Liabilities	67.69M	69.11M	100.9M	119.42M	135.08M	196.49M	193.98M	139.66M	146.92M
Total Debt	42.97M	44.22M	84.73M	97.67M	102.92M	154.44M	141.42M	82.12M	79.89M
Net Debt	-136.72K	21.47M	57.98M	41.75M	51.83M	67.92M	90.07M	-21.03M	-7.75M
Debt / Equity	1.07x	2.24x	3.23x	1.11x	0.73x	1.02x	1.05x	0.24x	0.17x
Debt / EBITDA	-	-	-	-	-	-	4.72x	0.56x	0.40x
Net Debt / EBITDA	-	-	-	-	-	-	3.01x	-0.14x	-0.04x
Interest Coverage	-12.32x	-10.90x	-4.37x	-5.32x	-4.49x	-2.42x	-0.13x	10.02x	26.69x
Total Equity	40.33M▲ 0%	19.77M▼ 51.0%	26.19M▲ 32.5%	88.25M▲ 236.9%	141.17M▲ 60.0%	151.97M▲ 7.7%	135.21M▼ 11.0%	349.02M▲ 158.1%	477.32M▲ 36.8%
Equity Growth %	1004.88%	-50.98%	32.49%	236.92%	59.97%	7.65%	-11.03%	158.14%	36.76%
Book Value per Share	1.76	0.44	0.48	1.02	1.01	0.77	0.60	1.43	1.95
Total Shareholders' Equity	40.33M	19.77M	26.19M	88.25M	141.17M	151.97M	135.21M	349.02M	477.32M
Common Stock	4.53K	4.63K	5.93K	10.49K	19.58K	22K	23K	24K	24K
Retained Earnings	-150.69M	-216.44M	-264.72M	-340.47M	-412.11M	-478.02M	-506.26M	-308.58M	-161.65M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.29M	-3.42M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

ADMA Cash Flow Statement

ADMA Biologics, Inc. (ADMA) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	-37.27M	-62.68M	-76.19M	-102M	-112.37M	-59.51M	8.8M	118.67M	50.4M
Operating CF Margin %	-163.76%	-369.02%	-259.61%	-241.6%	-138.82%	-38.62%	3.41%	27.83%	9.88%
Operating CF Growth %	-104.02%	-68.17%	-21.56%	-33.87%	-10.16%	47.04%	114.79%	1248.55%	-57.53%
Net Income	-43.76M	-65.74M	-48.28M	-75.75M	-71.65M	-65.9M	-28.24M	197.67M	146.93M
Depreciation & Amortization	2.69M	3.45M	3.26M	3.94M	5.5M	7.11M	8.33M	8.04M	8.1M
Stock-Based Compensation	1.56M	0	2.65M	2.86M	3.49M	5.21M	6.19M	13.62M	20.03M
Deferred Taxes	1.88M	122.19K	0	-910.1K	220.76K	0	0	-84.28M	11.02M
Other Non-Cash Items	638.73K	961.33K	-320.34K	1.64M	1.75M	12.35M	32.64M	2.16M	3.92M
Working Capital Changes	-282.24K	-3.69M	-33.5M	-33.78M	-51.68M	-18.29M	-10.12M	-18.54M	-139.59M
Change in Receivables	-2.86M	2.49M	-2.08M	-9.77M	-15.34M	13.07M	-11.92M	-22.58M	-108.43M
Change in Inventory	589.32K	-5.99M	-34.65M	-28.47M	-43.19M	-38.56M	-9.63M	2.67M	-36.23M
Change in Payables	2.81M	-20.48K	3.27M	1.9M	1.36M	799.98K	3.84M	4.15M	2.33M
Cash from Investing	15.21M	-2.1M	-3.81M	-12.72M	-13.51M	-13.91M	-4.98M	-8.57M	-21.89M
Capital Expenditures	-2.68M	-2.1M	-3.81M	-12.73M	-13.51M	-13.91M	-4.77M	-8.23M	-22.57M
CapEx % of Revenue	11.76%	12.34%	12.99%	30.14%	16.69%	9.03%	1.85%	1.93%	4.42%
Acquisitions	12.5M	0	0	2K	0	0	0	0	1M
Investments	-	-	-	-	-	-	-	-	-
Other Investing	12.5M	0	0	2K	0	0	-210K	-349K	-316K
Cash from Financing	60.75M	42.92M	80M	143.9M	121.05M	108.85M	-38.99M	-58.3M	-44.02M
Debt Issued (Net)	24.98M	-36.28K	42.47M	13.52M	-34K	51.71M	-23.6M	-60M	-3.17M
Equity Issued (Net)	39.2M	42.94M	48.4M	131.2M	121.14M	64.64M	-1.42M	7.49M	-28.96M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	-1.42M	0	-31.94M
Other Financing	-3.43M	13.01K	-10.86M	-816.57K	-62K	-7.51M	-13.97M	-5.8M	-11.89M
Net Change in Cash	38.69M▲ 0%	-21.85M▼ 156.5%	-2.72K▲ 100.0%	29.17M▲ 1073674.4%	-4.83M▼ 116.6%	35.43M▲ 833.3%	-35.17M▼ 199.3%	51.8M▲ 247.3%	-15.52M▼ 130.0%
Free Cash Flow	-39.95M▲ 0%	-64.77M▼ 62.1%	-80.01M▼ 23.5%	-114.73M▼ 43.4%	-125.88M▼ 9.7%	-73.42M▲ 41.7%	3.82M▲ 105.2%	110.1M▲ 2782.9%	27.82M▼ 74.7%
FCF Margin %	-175.51%	-381.36%	-272.6%	-271.74%	-155.52%	-47.65%	1.48%	25.82%	5.45%
FCF Growth %	-117.79%	-62.15%	-23.51%	-43.4%	-9.72%	41.68%	105.2%	2782.88%	-74.73%
FCF per Share	-1.74	-1.43	-1.47	-1.33	-0.90	-0.37	0.02	0.45	0.11
FCF Conversion (FCF/Net Income)	0.85x	0.95x	1.58x	1.35x	1.57x	0.90x	-0.31x	0.60x	0.34x
Interest Paid	0	0	8.11M	0	0	0	18.05M	10.67M	0
Taxes Paid	0	0	0	0	0	0	0	9.39M	0

ADMA Key Ratios

ADMA Biologics, Inc. (ADMA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-243.95%	-218.77%	-210.08%	-132.38%	-62.46%	-44.96%	-19.67%	81.65%	35.56%
Return on Invested Capital (ROIC)	-216.68%	-127.95%	-111.05%	-49.55%	-45.47%	-27.11%	-14.3%	7.29%	37.68%	36.01%
Gross Margin	40.34%	-28.14%	-148.42%	-34.6%	-45.17%	1.45%	22.89%	34.44%	51.48%	57.39%
Net Margin	-183.05%	-192.26%	-387.06%	-164.5%	-179.41%	-88.52%	-42.77%	-10.94%	46.35%	28.8%
Debt / Equity	-	1.07x	2.24x	3.23x	1.11x	0.73x	1.02x	1.05x	0.24x	0.17x
Interest Coverage	-7.71x	-12.32x	-10.90x	-4.37x	-5.32x	-4.49x	-2.42x	-0.13x	10.02x	26.69x
FCF Conversion	0.94x	0.85x	0.95x	1.58x	1.35x	1.57x	0.90x	-0.31x	0.60x	0.34x
Revenue Growth	48.53%	113.49%	-25.37%	72.79%	43.85%	91.72%	90.36%	67.58%	65.15%	19.63%

ADMA SEC Filings & Documents

ADMA Biologics, Inc. (ADMA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

May 4, 2026·SEC

Material company update

Mar 27, 2026·SEC

10-K Annual Reports

FY 2026

Feb 25, 2026·SEC

FY 2025

Mar 18, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

ADMA Frequently Asked Questions

ADMA Biologics, Inc. (ADMA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

ADMA Biologics, Inc. (ADMA) reported $510.2M in revenue for fiscal year 2025.

ADMA Biologics, Inc. (ADMA) grew revenue by 19.6% over the past year. This is strong growth.

Yes, ADMA Biologics, Inc. (ADMA) is profitable, generating $146.9M in net income for fiscal year 2025 (28.8% net margin).

Dividend & Returns

ADMA Biologics, Inc. (ADMA) has a return on equity (ROE) of 35.6%. This is excellent, indicating efficient use of shareholder capital.

ADMA Biologics, Inc. (ADMA) generated $27.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More ADMA

ADMA Biologics, Inc. (ADMA) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

ADMA Biologics, Inc.(ADMA)Earnings, Financials & Key Ratios

ADMA Key Insights

✓Strengths

✗Weaknesses

ADMA Price & Volume

ADMA Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

ADMA Recent Earnings

ADMA Peer Comparison

Compare ADMA vs Peers

vs GRFS

vs TAK

Compare Top 5

ADMA Income Statement

ADMA Balance Sheet

ADMA Cash Flow Statement

ADMA Key Ratios

ADMA SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

ADMA Frequently Asked Questions

Explore More ADMA

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation